secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2025-10-07T23:59:59+00:00
Accession:  0001171843-25-006316
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus announces four abstracts accepted for AASLD, including AB-101 Poster of Distinction
--------------------------------------------------------------------------------

- Three abstracts on imdusiran and one on AB-101 accepted for AASLD Liver Meeting Nov 7-11, 2025 in Washington DC.
- Imdusiran integrated safety analysis shows well-tolerated at 60-90 mg Q8W for up to 48 weeks dosing and follow-up.
- Imdusiran may enhance pegylated interferon responsiveness in HBV genotype B/C patients vs historical data.
- AB-101 up to 30 mg QD for 28 days was well tolerated; 83% mean PD-L1 receptor occupancy at 30 mg dose.
- AB-101 abstract selected as Poster of Distinction; data on safety, PK, PD and HBV biomarkers will be presented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325006316/0001171843-25-006316-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325006316/f8k_100625.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-006316

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer